Skip to content
Reipet – Lifestyle
Author:
Connect Biopharma Holdings Limited
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
September 15, 2026
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
June 17, 2026
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 21, 2026
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 13, 2026
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
April 26, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 30, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
1
2
Next Page
→